1026622-55-8

Basic information

• Product Name: [(E)-4-(5-Methyl-2-phenyl-oxazol-4-ylmethoxy)-benzyloxyimino]-(4-phenoxy-phenyl)-acetic acid ethyl ester
• CAS NO: 1026622-55-8
• Molecular Weight: 562.622
• Mol File: 1026622-55-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: [(E)-4-(5-Methyl-2-phenyl-oxazol-4-ylmethoxy)-benzyloxyimino]-(4-phenoxy-phenyl)-acetic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: [(E)-4-(5-Methyl-2-phenyl-oxazol-4-ylmethoxy)-benzyloxyimino]-(4-phenoxy-phenyl)-acetic acid ethyl ester(1026622-55-8)
• EPA Substance Registry System: [(E)-4-(5-Methyl-2-phenyl-oxazol-4-ylmethoxy)-benzyloxyimino]-(4-phenoxy-phenyl)-acetic acid ethyl ester(1026622-55-8)

Safety Data

• Hazardous Substances Data: 1026622-55-8(Hazardous Substances Data)

Upstream product

• 250602-53-0 4-{[4-(chloromethyl)phenoxy]methyl}-5-methyl-2-phenyl-1,3-oxazole 
• 250602-60-9 ethyl (E)-2-(hydroxyimino)-2-(4-phenoxyphenyl)acetate 
• 101-84-8 diphenylether 
• 62936-33-8 ethyl 2-oxo-2-(4-phenoxyphenyl)acetate 
• 103789-66-8 4-(5-methyl-2-phenyl-4-oxazolylmethoxy)-benzaldehyde 
• 250602-52-9 {4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl}methanol 

Downstream Products

• 250601-08-2 (E)-2-{4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}-2-(4-phenoxyphenyl)acetic acid 

Relevant articles and documents

Studies on non-thiazolidinedione antidiabetic agents. 1. Discovery of novel oxyiminoacetic acid derivatives

A novel series of oxyiminoacetic acid derivatives were synthesized in an effort to develop a potent antidiabetic agent, which does not contain the 2,4-thiazolidinedione moiety. These compounds were evaluated for glucose and lipid lowering effects in genetically obese and diabetic KKAy mice. Several of the compounds showed strong antidiabetic activity, including functional potency at peroxisome proliferator-activated receptor (PPAR)-γ. (Z)-2-[4-[(5-Methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino]-2-(4- phenoxyphenyl)acetic acid (25) significantly reduced plasma glucose (33%, p0.01) and plasma triglycelide levels (43%, p0.01) even at a dosage of 0.001% in diet. Pharmacokinetic analyses of 25 are also reported.